Marker Therapeutics

Marker Therapeutics, Inc. is a clinical-stage immuno-oncology company specializing in the development of next-generation T cell-based immunotherapies for the treatment of hematological malignancies and solid tumor indications.
Marker Therapeutics stock price chart
vol.
change
P/E
Net profit
P/B
Book value
P/FCF
FCF
Yield
Growth potential

Marker Therapeutics balance sheet

Report period2016 2017 2018 2019 2020 2021
End date of the reporting period
Capitalization, $
Capitalization, $
Enterprise Value
Book Value
Shareholders Book Value
Current liabilities
Noncurrent liabilities
Total liabilities
Debt
Cash and cash equivalents
Net debt
Assets
Total ordinary shares
Ordinary share price

Marker Therapeutics cash flows

Report period2016 2017 2018 2019 2020 2021
End date of the reporting period
Sales
Gross profit
Operation Income
Earnings
Shareholders earnings
EBITDA
Operation Cashflow
Capital expenditure
Free Cash Flow
EPS

Marker Therapeutics multipliers

Report period2016 2017 2018 2019 2020 2021
P/E
E/P
P/B
P/S
P/FCF
L/A
Debt-To-Equity
Net Debt/EBITDA
EV/EBITDA

Marker Therapeutics profitability

Report period2016 2017 2018 2019 2020 2021
ROA
ROE
ROS
EBITDA Margin
Operating margin
Marker Therapeutics assets
Marker Therapeutics cash flows

Marker Therapeutics shares

TickerNameTypeNominal valueISINPrice
MRKR:USMarker TherapeuticsCommon share-US57055L1070$4
Marker Therapeutics news
13.05.2022
Marker Therapeutics' GAAP loss for 3 months of 2022 was $9.91 million, up 12.9% from $8.779 million in the prior year. Revenue was $964,322,000. The company did not generate revenue a year earlier.
18.03.2022
Marker Therapeutics' GAAP loss for 2021 was $41.879 million, up 45.9% from $28.706 million in the prior year. Revenue increased 2.7 times to $1.242 million from $0.466 million a year earlier.
20.01.2022
FDA has granted orphan drug status to MT-601, which is being developed by Marker Therapeutics. The drug is intended to treat people with pancreatic cancer and contains multiple tumor antigens. Drugs with this status can receive grants from the FDA to cover the costs of clinical trials, tax credits and seven years of market exclusivity in the U.S. after appro...
11.11.2021
Marker Therapeutics' GAAP loss for 9M 2021 was $32.116 million, up 59% from $20.199 million in the prior year. The company did not generate revenue. A year earlier, the figure was $466,785 thousand.
General information
Company nameMarker Therapeutics
SectorHealth Care / Pharmaceuticals, Biotechnology & Life Sciences / Biotechnology / Biotechnology
Business address3200 SOUTHWEST FREEWAY SUITE 2240 HOUSTON TX 77027 (713) 400-6400
Mailing address3200 SOUTHWEST FREEWAY SUITE 2240 HOUSTON TX 77027
Websitewww.markertherapeutics.com
Information disclosurewww.sec.gov